

New Hampshire Medicaid Fee-for-Service (FFS) Program **Prior Authorization/Non-Preferred Drug Approval Form**

Duloxetine

DATE OF MEDICATION REQUEST: /	/
-------------------------------	---

SE	СТІО	N I: P	ATIE	NT IN	NFOF	RMA	ΓΙΟΝ	ANI) ME	DIC	CATIO	ON R	REQUI	STEI)										
LA:	ST NA	AME:											FIRST NAME:												
ME	DICA	AID ID	NUI	MBEF	₹:	<u> </u>		<u> </u>	1				DAT	E OF	BIRT	H:		1	1	1					
]_]_]		
GE	NDEF	- ₹:		Male	<u> </u>	Fe	emale	 e										_]		
Drı	ug Na	me:			-												Strer	ngth:							
Do	Dosing Directions:														Leng	th of	Thei	ару:							
SE	СТІО	N II: F	PRES	CRIB	ER IN	IFOR	MAT	ION																	
LA:	ST NA	AME:										_	FIRS	T NA	ME:										
SPI	ECIAL	TY:				<u> </u>							NPI	NUM	BER:			<u> </u>							
PH	ONE	NUM	BER:									_	FAX	NUN	 BER	<u> </u>]		
] _				_ [7] _				1_					
]				L																		
SE	СТІО	N III:	CLIN	ICAL	HIST	ORY	,																		
1.	Doe	s the	patie	ent h	ave a	diag	gnosi	s of	a de _l	pre	ssive	disc	order	If ye	es, go	to qu	uestio	on 11				Y	es [No	
2.	Doe	s the	patie	ent h	ave a	diag	gnosi	s of	gene	eral	ized	anxi	ety di	sorde	er? <i>If</i>	yes, <u>c</u>	go to	ques	tion	11.		Y	es [No	
3.	Doe	s the	patie	ent h	ave a	diag	gnosi	s of	diab	etic	peri	iphe	ral ne	urop	athy?)						Y	es [No	
4.	If YE	S to 0	quest	tion 3	3, ha	s the	patie	ent e	expe	rier	nced	a tre	eatme	nt fa	ilure,	or is	not a	a can	didat	e for		Y	es [No	
		tmen							llow	ing	age	nts: a	any tr	icycli	c ant	idepr	essaı	nt or	gaba	pent	in?				
	LIST	treat	men	таш	ure a	na a	ates:																		

(Form continued on next page.)

© 2016–2022 by Magellan Rx Management, LLC. All rights reserved. **Phone**: 1-866-675-7755 **Fax**: 1-888-603-7696

Review Date: 10/28/2022





New Hampshire Medicaid Fee-for-Service (FFS) Program Prior Authorization/Non-Preferred Drug Approval Form

Duloxetine

			0	ATE	OF	MED	ICAT	ΠΟΝ	IREC	QUES	ST:		/												
PA	TIE	NT I	LAS1	ΓNA	ME:									PA	TIENT	FIRS	T NA	ME:							
						1						I.		J L		<u> </u>		1	1	1		1	1		
SE	СТІ	ON	III: C	CLIN	ICAL	HIST	ΓORY	(Co	ntin	ued))														
5.	Do	es t	he p	oatie	nt h	ave a	dia	gnos	sis of	fibr	omy	alg	ia? <i>I</i>	f yes,	go to	quest	ions 6	5- <i>9</i> .					Y	es [No
6.	На	s w	ides	prea	d pa	in be	een p	rese	ent f	or at	t leas	st 3	mo	nths?									Y	es [No
7.	ls	pain	pre	sent	in a	ıt lea	st 11	. out	of t	he 1	.8 sp	ecif	fic te	nder	points	acc	ordin	g to /	ACR g	guide	lines)	?	Y	es [No
8.						y phy e and				inter	vent	tior	ns th	at hav	e bee	en dor	ne. If	addi	tiona	l spa	ce is				
9.	ca	ndic	-	for	reat	•		_			•			experi lowing						, or is	s not	 a	<u></u> Y	ES [NO
	a.	Lis	t tre	atm	ent i	failur	e, m	axin	num	dos	es fa	iled	d, an	d date	es:										
10.	 . Do	es t	the p	atie	nt h	ave a	dia;	gnos	sis of	chr	onic	mu	ıscul	oskele	etal pa	ain?							ПΥ	ES [□NO
	a.	Ple	ease	des	cribe	2:																			
	b.	-		-					-		-			d a tre							didate	<u>—</u>	Y	ES [] NO
11.	. Is t	the	pati	ent (curre	ently	on p	rega	abali	n or	miln	naci	iprar	1?									Y	ES [NO
12.				-		onal i lease						ld h	nelp	in the	decis	ion-m	ıaking	g pro	cess?	o If ac	lditio	nal			
13			•				-						-	inkle i		ed Dr	ug Ap	oprov	/al Cr	iteria	a).		Y	ES [NO
(Fc	orm	con	ntinu	ed c	n ne	xt po	age.)																		

Phone: 1-866-675-7755 **Fax**: 1-888-603-7696





New Hampshire Medicaid Fee-for-Service (FFS) Program Prior Authorization/Non-Preferred Drug Approval Form

Duloxetine

DATE OF MEDICATION REQUEST: / /
PATIENT LAST NAME: PATIENT FIRST NAME:
SECTION IV: NON-PREFERRED DRUG APPROVAL CRITERIA
Chapter 188 of the Laws of 2004 requires that Medicaid only cover non-preferred drugs upon a finding of medical necessity by the prescribing physician. Chapter 188 requires that you base your determination of medical necessity on the following criteria.
Allergic reaction. Describe reaction:
Drug-to-drug interaction. Describe reaction :
Previous episode of an unacceptable side effect or therapeutic failure. Provide clinical information:
Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to a preferred drug.
Provide clinical information:
Age specific indications. Provide patient age and explain:
Unique clinical indication supported by FDA approval or peer reviewed literature. Explain and provide a reference:
Unacceptable clinical risk associated with therapeutic change. Please explain:
I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.
PRESCRIBER'S SIGNATURE: DATE:

Phone: 1-866-675-7755 **Fax**: 1-888-603-7696

